PMID: 15371284Sep 17, 2004Paper

What is new in lymphoma?

CA: a Cancer Journal for Clinicians
Bruce D Cheson

Abstract

The lymphomas are a diverse group of malignant disorders that vary with respect to their molecular features, genetics, clinical presentation, treatment approaches, and outcome. Over the past few years, there have been major advances in our understanding of the biology of these diseases, leading to a universally adopted World Health Organization classification system. New therapies are now available with the potential to improve patient outcome, and the International Prognostic Index and standardized response criteria help make clinical trials interpretable. Most notably, the chimeric antiCD20 monoclonal antibody rituximab has altered our therapeutic paradigms for B-cell disorders. Combinations of this antibody with chemotherapy and other biologic agents have shown promise in treating lymphoma. Other antibodies, radioimmunoconjugates (such as Y-90 ibritumomab tiuxetan and I-131 tositumomab), and oblimerson sodium (a BCL-2 antisense oligonucleotide) have all shown promise. New chemotherapy regimens such as bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP), agents such as gemcitabine, and monoclonal antibodies directed against CD30 are also being studied in Hodgkin Lymphoma. T...Continue Reading

Citations

Jul 8, 2005·Expert Review of Proteomics·Julia Tait LathropDavid J Hammond
Jun 17, 2009·Expert Opinion on Pharmacotherapy·David Masiello, Anil Tulpule
Oct 17, 2009·Cancer Investigation·Jennifer L KellySusan G Fisher
Sep 25, 2012·Gene·Sara KhansaRami A R Mahfouz
Dec 13, 2006·Radiologic Clinics of North America·Jürgen Rademaker
Jan 18, 2006·Blood Reviews·Vikas Aurora, Jane N Winter
May 3, 2007·Clinical Journal of Oncology Nursing·Kimberly Noonan
Mar 17, 2006·Nature Reviews. Microbiology·Nikolaus OsterriederSascha Trapp
Jul 18, 2017·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marcello PersicoMario Masarone
Feb 27, 2008·Acta Pharmacologica Sinica·Lin LiuPing Zou
Sep 25, 2010·Journal of Cancer Research and Clinical Oncology·Kristina SchwambornAxel Wellmann
Jan 18, 2006·Annals of Hematology·Y H ParkUNKNOWN Lymphoma Study Division of the Korean Cancer Study Group
Dec 14, 2007·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Teruhiko TerasawaHirokazu Nagai
Apr 29, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S MonfardiniV Torri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.